Apexigenincis A Clinical Stage Biopharmaceutical Company Based In San Carloscaliforniafounded In 2010It Became A Subsidiary Of Pyxis Oncologyincin 2023Apexigen Focuses On Discovering And Developing Innovative Antibody Therapeuticsprimarily For Oncologyinflammatory Diseasesand Ophthalmic Conditions The Company S Pipeline Includes Several Key Productsapx005M Is A Humanized Agonist Antibody Currently In Phase Ii Trials For Various Solid Tumorstested Alongside Immunotherapy And Chemotherapyapx601 Is A Humanized Antagonist Antibody In Phase I Ii Trials For Multiple Tumor Typesadditionallyapx801 Is Designed To Activate Natural Killer Cells For Tumor Destructionapexigen Utilizes Its Proprietary Apximaba C Platform For The Rapid Discovery Of Humanized Monoclonal Antibodies With Enhanced Therapeutic Potential
